GlassScriptPhysician profile
Courtney Bartley
NPI 1598298051
$59,606.88
in general payments reported to CMS, 2019-2025
18 companies · $35K in 2025
The $35K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $30.24 · 2022: $84.02 · 2023: $8,298 · 2024: $17K · 2025: $35K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $28K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18K · Travel and Lodging: $8,322 · Food and Beverage: $4,465 · Consulting Fee: $560 · Education: $19.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $27,866.20 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,260.00 |
| Travel and Lodging | $8,322.17 |
| Food and Beverage | $4,465.00 |
| Consulting Fee | $560.00 |
| Education | $19.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braeburn INC. | $37,134.42 | 2023-2025 | Brixadi |
| Alkermes, INC. | $20,783.29 | 2023-2025 | Vivitrol, Vivitrol, Aristada |
| Abbvie INC. | $376.12 | 2022-2025 | |
| Gilead Sciences, INC. | $366.35 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $203.97 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Axsome Therapeutics, INC. | $150.24 | 2023-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $125.09 | 2023-2025 | Caplyta |
| Uswm, LLC | $102.50 | 2023 | Zimhi, Lucemyra |
| Otsuka America Pharmaceutical, INC. | $88.89 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Indivior INC. | $54.28 | 2022-2024 | Sublocade |
| Janssen Pharmaceuticals, INC | $49.27 | 2022-2025 | Invega Sustenna, Invega Trinza |
| E.R. Squibb & Sons, L.L.C. | $47.39 | 2024 | |
| Organon LLC | $33.43 | 2023 | Nexplanon |
| Novo Nordisk INC | $30.24 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $17.76 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $15.01 | 2024 | Rexulti |
| Orexo US, INC. | $14.39 | 2023 | Zubsolv |
| Lilly USA, LLC | $14.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Courtney Bartley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.